A Study to Assess BMS-986453 in Participants With Relapsed and/​or Refractory Multiple Myeloma

The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).

Sponsor

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Status of enrollment

Open to accrual

Ages Eligible for Study

Adults aged 18 years and up

Genders Eligible for Study

Males or Females

Disease indication

Relapsed and/or Refractory Multiple Myeloma

Principal Investigator

Alfred Chung, MD

Contact

Colan Tizon
[email protected]
 

 

Additional study eligibility details can be found at UCSF Clinical Trials.